Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DimoVena is a cosmetic topical foam developed by Kéri Pharma, a Hungarian pharmaceutical company. It is specifically formulated to provide relief for tired and heavy legs, symptoms often associated with chronic venous insufficiency. The product features a triple-action composition of active ingredients: diosmin, menthol, and panthenol. Menthol acts as a cooling agent by stimulating TRPM8 receptors, providing an immediate refreshing sensation. Diosmin, a bioflavonoid, is included for its traditional venotonic and vasoprotective properties, which help improve microcirculation and reduce the feeling of heaviness. Panthenol (provitamin B5) serves as a skin-conditioning agent to soothe and protect the skin. DimoVena is delivered as a "crackling foam" (sercegő hab), a specialized formulation that enhances the cooling and sensory effect upon application. It is marketed as a cosmetic product rather than a pharmaceutical medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DimoVena.